CD79A and COVID-19: However, while glycomic studies of IgA have demonstrated a correlation between glycosylation profiles of IgA and the pathomechanisms of diseases such as IgA nephropathy or rheumatoid arthritis (7–11), the glycosylation signatures of plasma IgA obtained from patients with severe COVID-19 remained largely unexplored.